KVK-Tech Inc, a company that develops and manufactures high-quality, FDA-approved medicines, and its affiliate Penn Life Sciences Inc announced on Monday that Ram Kamineni has been appointed as chief operating officer.
Kamineni has over 38 years of pharma industry experience. He has served as the SVP, head of Global Operations for Jubilant Pharma, VP, head of Global OSD Manufacturing Strategy for Mylan. He also had various roles in companies such as Novartis, Patheon, and Merck Generics.
KVK and PLS CEO, Anthony Tabasso, was quoted as saying: "We are extremely pleased and excited to welcome Ram as our chief operating officer. With his unique experience and hands-on leadership philosophy, he is an excellent fit. We are confident Ram's knowledge and expertise will further advance our goal to establish our company as a leader in the generics industry. I look forward to working closely with him as we build on our strong foundation to drive sustainable growth, with an emphasis on quality and compliance."
Par Pharmaceutical starts shipping colchicine 0.6mg capsules
Padagis launces Brinzolamide Ophthalmic Suspension with CGT exclusivity
Novartis completes Sandoz Spin-off
Novartis completes Sandoz spin-off, focusing on innovative medicines
Hikma marks KLOXXADO two-year anniversary by surpassing 375,000 doses donated in the US
STADA seeks full approval for Kinpeygo in IgA nephropathy from UK MHRA
Azurity Pharmaceuticals completes Slayback Pharma acquisition
Sandoz secures European approval for Tyruko biosimilar in MS treatment
Senores Pharmaceuticals introduces Nicardipine Hydrochloride Capsules USP, 20mg and 30mg in US
Lupin collaborates with Mark Cuban Cost Plus Drug Company and COPD foundation
Certara Simcyp receives FDA grants for advanced pharmacokinetic modelling
Sandoz's Tyruko (natalizumab-sztn) gains FDA approval as first biosimilar for relapsing MS
Nephron Pharmaceutical names new chief procurement officer
Lupin Pharmaceuticals launches Tiotropium Bromide Inhalation Powder, 18mcg/capsule in US